ImmunityBio Files Prospectus Amid Layoffs and Cash Constraints Following FDA Approval of First-in-Class IL-15 Drug Anktiva
ImmunityBio
Developer of Immunotherapy Products
▲October 26-27, Chengdu
China Clinical Trials Industry Development ConferenceClick to register for free
Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must be authorized.
This California-based pharmaceutical manufacturer is cutting jobs in California and Colorado.20Employees, some of whom work remotely.
Previously affected byFDAAfter being neglected, with the reduction of funds,ImmunityBioFor its bladder cancer drug competing with MerckAnktiva The journey to gain approval was not easy. Now, having finally crossedFDAA few months after the finish line, this California-based pharmaceutical manufacturer is turning to layoffs to cut costs.
According to the state's Worker Adjustment and Retraining Notification (WARN) Notice, the company will lay off employees at several offices in California and one office in Colorado by the end of this month.20Name of the employee.
The company's human resources team wrote in a notice to Florida officials that some of the affected employees work remotely, such as a technical analyst in Florida. Positions on the chopping block include quality control and supply chain management managers, deputy directors of procurement and strategic sourcing.ITSupport and other manufacturing positions. All layoffs will take place on10Month29Effective on [Date].
ImmunityBio In the notice to the governors of the affected states, these measures were described as being aimed at "better aligning operations to support the company's ongoing business strategy, reducing layoffs, and improving financial efficiency."
The company spokesperson said that it would not comment on this for the time being.
Mechanism of Action of Anktiva
Copyright Statement: This article is reproduced fromThe Era of Biologics，Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
[About PharmaCircle]
PRHub of Yaorong Circle aims to assist biopharmaceutical technology enterprises in brand promotion and business development services. It provides systematic solutions based on customers' real needs, making brand information easily understandable to the public through "translation-simplification-scenario application." At the same time, it achieves cooperation goals with access to over 1 million vertical users across traffic channels, helping partners complete a closed-loop marketing service from branding to business. We have successfully organized dozens of offline biopharmaceutical R&D conferences with a scale of 1,000 attendees, covering fields such as small-molecule new drugs, large-molecule new drugs, improved new drugs, and cross-border BD transactions, serving more than a hundred listed/unicorn/biotech/pharmaceutical companies.
